DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07178145

RecruitingPhase 4

Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction

MRI of Epicardial Adipose Tissue Composition: Development of Methods and Application to Heart Failure With Preserved Ejection Fraction

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

192

estimated

Study population

Heart failure

Key I/E criterion

•EF ≥50%

Primary endpoint

•Epicardial adipose tissue (EAT) fatty acid composition (FAC)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07178145
Org study ID302641

Timeline

Milestones

Study first posted2025-09-17actual
Study start2025-11-20actual
Last update posted2026-05-05actual
Primary completion2029-09estimated (month precision)
Study completion2029-12estimated (month precision)

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Heart failure

Eligibility

Who can enroll

Minimum age18 Years
Maximum age90 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Age ≥ 18 years - 90 years;
•LVEF ≥ 50%;
•≥ 2 risk factors for HFpEF or symptoms that could be related to HFpEF (e.g., dyspnea, orthopnea, paroxysmal nocturnal dyspnea, lower extremity edema, pulmonary edema, etc);
•Not currently being treated with GLP-1RA therapy.

Exclusion criteria

•• Previously or currently reduced EF (<50%), including heart transplant; (2) Obstructive un-revascularized coronary disease by coronary CT or invasive coronary angiography;
–MI/PCI/CABG within the past 6 months;
–Untreated severe stenotic or regurgitant valvular disease;
–Infiltrative cardiomyopathy (Fabry/HCM/sarcoid/amyloid, etc);
–Myocarditis;
–Claustrophobia/inability to tolerate MRI;
–Implants that are a contraindication for MRI or may negatively impact image quality (e.g. pacemakers and ICDs);
–Active systemic inflammatory disorder;
–Atrial fibrillation with rapid ventricular response at time of study; and
–Hemodynamic instability
–Pregnancy
–Prisoners
–Inability to provide informed consent

Exclusion Criteria for Optional Cardiac Stress Imaging Procedure

•allergy to gadolinium-based contrast agents
•Acute kidney injury
•Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m²
•Hepatorenal syndrome
•History of liver transplant
•High-grade atrioventricular (AV) block
•Active asthma exacerbation
•Known allergy to vasodilator agents
•Recent seizure

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Weight & body composition
1
Heart failure
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

EAT Volume

Time frame:Baseline, 3months (self-control period), and 9-months (6 months post semaglutide treatment)

Visceral fat, change

change from baseline, improvement

Heart failure

1 endpoint
Secondary/protocol endpoint/low confidence

Baseline Saturated Fatty Acid Composition of Epicaridal Adipose Tissue and Change in diastolic dysfunction grade

Time frame:Baseline, 3months (self-control period), and 9-months (6 months post semaglutide treatment)

change from baseline, improvement

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Epicardial adipose tissue (EAT) fatty acid composition (FAC)

Time frame:Baseline, 3 months (self-control period), and 9-months (6 months post semaglutide treatment)

percent change from baseline, improvement

Secondary/protocol endpoint/low confidence

Baseline Saturated Fatty Acid Composition of Epicaridal Adipose Tissue and Change in Myocardial Deformation

Time frame:Baseline, 3months (self-control period), and 9-months (6 months post semaglutide treatment)

change from baseline, improvement

Publications (36)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.